Investment Thesis
Black Diamond Therapeutics is a pre-revenue biotech company with zero revenue generation, negative operating cash flow of -$10.2M, and deteriorating profitability. At current burn rates, the company has approximately 3 quarters of cash runway remaining ($30.1M / ~$10.2M quarterly burn), creating near-term funding pressure without demonstrated commercial progress.
Strengths
- Strong liquidity position with 8.46x current ratio providing short-term financial flexibility
- Low leverage with 0.00x debt-to-equity ratio minimizing financial distress risk
- Positive stockholders' equity of $104.3M providing some balance sheet cushion
Risks
- Zero revenue with no path to profitability visible in current fundamentals
- Accelerating cash burn rate of -$10.2M per quarter with limited runway before capital depletion
- Highly dilutive capital structure evidenced by negative diluted EPS of -$0.16, destroying shareholder value
- Typical biotech funding risk requiring additional capital raises likely to dilute existing shareholders
Key Metrics to Watch
- Quarterly operating cash burn rate and remaining cash runway
- Time to first revenue generation or clinical milestone announcements
- Capital raise requirements and dilution impact
- Operating expense trends and burn rate trajectory
Financial Metrics
Revenue
0.0
Net Income
-9.0M
EPS (Diluted)
$-0.16
Free Cash Flow
-10.2M
Total Assets
132.9M
Cash
30.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-8.7%
ROA
-6.8%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
8.46x
Quick Ratio
8.46x
Debt/Equity
0.00x
Debt/Assets
21.5%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T07:55:54.646975 |
Data as of: 2026-03-31 |
Powered by Claude AI